Bioprocess

Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Retrieved on: 
Wednesday, May 12, 2021

A rise in new disease outbreaks, the urgency to launch innovative therapies, and new constructs such as multi-valent antibodies are compelling biopharmaceutical companies to adopt new manufacturing approaches.

Key Points: 
  • A rise in new disease outbreaks, the urgency to launch innovative therapies, and new constructs such as multi-valent antibodies are compelling biopharmaceutical companies to adopt new manufacturing approaches.
  • The industry must reduce costs and achieve scalability of downstream processes in global sites to work more efficiently.
  • Biopharmaceutical companies must follow suit by adopting advanced manufacturing technologies, establishing public-private partnerships and placing sustainability at the core of the business strategy.\nFrost & Sullivan\'s latest article, Preparing for Next Generation of Biopharmaceutical Manufacturing, analyzes six dynamic trends that will impact the future of biopharmaceutical manufacturing.
  • "\nOverall, biopharmaceutical companies need to review investments beyond the traditional growth levers of clinical and commercial excellence and intensify efforts related to sustainability.

Discover Six Dynamic Trends to Disrupt the Next Generation of Biopharmaceutical Manufacturing

Retrieved on: 
Wednesday, May 12, 2021

A rise in new disease outbreaks, the urgency to launch innovative therapies, and new constructs such as multi-valent antibodies are compelling biopharmaceutical companies to adopt new manufacturing approaches.

Key Points: 
  • A rise in new disease outbreaks, the urgency to launch innovative therapies, and new constructs such as multi-valent antibodies are compelling biopharmaceutical companies to adopt new manufacturing approaches.
  • The industry must reduce costs and achieve scalability of downstream processes in global sites to work more efficiently.
  • Biopharmaceutical companies must follow suit by adopting advanced manufacturing technologies, establishing public-private partnerships and placing sustainability at the core of the business strategy.\nFrost & Sullivan\'s latest article, Preparing for Next Generation of Biopharmaceutical Manufacturing, analyzes six dynamic trends that will impact the future of biopharmaceutical manufacturing.
  • "\nOverall, biopharmaceutical companies need to review investments beyond the traditional growth levers of clinical and commercial excellence and intensify efforts related to sustainability.

Maravai LifeSciences Announces Investor Conference Schedule for the Month of May 2021

Retrieved on: 
Wednesday, May 5, 2021

b"SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of May.\nOn\xc2\xa0May 12, 2021, Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Bank of America Global Healthcare Conference at\xc2\xa010:15 a.m. PT.\nOn\xc2\xa0May 25, 2021, Carl Hull, Chief Executive Officer will participate in a fireside chat at the UBS Global Healthcare Conference at 2:00 p.m. PT.\nA live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at http://investors.maravai.com .

Key Points: 
  • b"SAN DIEGO, May 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of May.\nOn\xc2\xa0May 12, 2021, Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Bank of America Global Healthcare Conference at\xc2\xa010:15 a.m. PT.\nOn\xc2\xa0May 25, 2021, Carl Hull, Chief Executive Officer will participate in a fireside chat at the UBS Global Healthcare Conference at 2:00 p.m. PT.\nA live webcast of the presentations will be available to all interested parties on the Maravai Lifesciences investor relations website at http://investors.maravai.com .
  • An archived version of the webcast will be available a few hours following the completion of each event on the Maravai investor relations website.\nMaravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases.
  • Maravai\xe2\x80\x99s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.\nFor more information about Maravai LifeSciences, visit www.maravai.com .\n"

Siemens Releases gPROMS FormulatedProducts 2.0 – New Application Areas and Key Usability Enhancements

Retrieved on: 
Tuesday, April 27, 2021

b'Process Systems Enterprise (PSE), A Siemens Business, today announced the full release of gPROMS FormulatedProducts 2.0, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation.\nThis press release features multimedia.

Key Points: 
  • b'Process Systems Enterprise (PSE), A Siemens Business, today announced the full release of gPROMS FormulatedProducts 2.0, the mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210427005797/en/\ngPROMS FormulatedProducts 2.0 is a mechanistic model-based environment for integrated digital design of robust formulated products and their manufacturing processes, and related digital process operation.
  • It is used in the pharmaceuticals, food & beverage and FMCG sectors for active ingredient manufacture, formulation manufacture, product performance and bioprocessing.
  • Workflows when specifying buffers and media compositions of in vitro vessel, solution and suspension dosage forms have been streamlined, and equilibrium limited reactions added to the chemical synthesis libraries.

Waters and Genovis Collaborate to Develop Efficient Workflows for Biopharmaceutical Characterization

Retrieved on: 
Tuesday, April 13, 2021

b'Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters\xe2\x84\xa2 BioAccord\xe2\x84\xa2 LC-MS System , Andrew+ pipetting robot and Genovis SmartEnzymes\xe2\x84\xa2 .

Key Points: 
  • b'Waters Corporation (NYSE:WAT) and Genovis AB (Nasdaq First North Growth Market) are formally collaborating to develop and market complete routine biopharmaceutical characterization workflows based on the Waters\xe2\x84\xa2 BioAccord\xe2\x84\xa2 LC-MS System , Andrew+ pipetting robot and Genovis SmartEnzymes\xe2\x84\xa2 .
  • The goal of the collaboration is to develop automated workflows for the rapid and consistent characterization of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) and other protein-based drugs in bioprocess development, formulation, stability testing and quality control (QC).\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210413005369/en/\n\xe2\x80\x9cBiologics analysis is an area that is ripe for improvement.
  • What takes analytical scientists several days to do, should take hours or minutes instead,\xe2\x80\x9d said Jeff Mazzeo, Vice President, Global Marketing and Scientific Operations, Waters Corporation.

Qosina Announces Expanded Portfolio for Bioprocess Single-use Systems

Retrieved on: 
Tuesday, April 13, 2021

Qosina now offers a comprehensive selection of components for the design, development and manufacture of single-use systems (SUS).\nThis press release features multimedia.

Key Points: 
  • Qosina now offers a comprehensive selection of components for the design, development and manufacture of single-use systems (SUS).\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210413005188/en/\nQosina offers more than 1,000 stock components for bioprocess single-use systems (Photo: Business Wire)\n\xe2\x80\x9cQosina has been a trusted supplier for over 40 years and has worked with some of the best-known brands,\xe2\x80\x9d explains Scott Herskovitz, Qosina President and CEO.
  • \xe2\x80\x9cOur experience serving the needs of regulated customers positions us well to expand our products and services for the single-use bioprocess community.
  • Qosina offers free samples of most items, low minimum order requirements, just-in-time delivery, modification of existing molds, and new product design and development.

WuXi Biologics Receives 2021 Asia-Pacific Bioprocessing Excellence Award from IMAPAC

Retrieved on: 
Tuesday, April 13, 2021

b'SHANGHAI, April 13, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK),a global company with leading open-access biologics technology platforms,announced that it has been recognized as the grand winner of theBioprocessing Excellence in Greater China Region Awardin two prestigious categories: the Bioprocessing Excellence in Antibody & ADC Therapeutics Manufacturing in Greater China Region and the Bioprocessing Excellence in Viral Clearance and Safety in Greater China Region at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2021.\nAsia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality across Asia and the rest of the world.\n"We are honored to be recognized as the winner in such important categories," said Dr. Chris Chen, CEO of WuXi Biologics.

Key Points: 
  • b'SHANGHAI, April 13, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK),a global company with leading open-access biologics technology platforms,announced that it has been recognized as the grand winner of theBioprocessing Excellence in Greater China Region Awardin two prestigious categories: the Bioprocessing Excellence in Antibody & ADC Therapeutics Manufacturing in Greater China Region and the Bioprocessing Excellence in Viral Clearance and Safety in Greater China Region at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2021.\nAsia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence at enhanced speed, reduced cost and superior quality across Asia and the rest of the world.\n"We are honored to be recognized as the winner in such important categories," said Dr. Chris Chen, CEO of WuXi Biologics.
  • "This is a tremendous testimony to WuXi Biologics\' outstanding services and our contribution to continuous optimization in bioprocessing technologiesand biologics manufacturing.We will continue our efforts in leveraging ourcapacities and capabilities, working in tandem with our clients to discover, develop,and manufacturing biologics,to benefit patients in a timely manner while maintaining world-class quality.
  • "\nAs of December 31, 2020, 40 integrated antibody-drug conjugate (ADC) projects are being developedon theWuXi Biologics\' platform.
  • For more information on WuXi Biologics, please visit www.wuxibiologics.com\n'

Global Single-use Bioprocessing Market Outlook 2021-2026: Increasing Strategic Acquisitions & Partnerships, New Product Launches, & Technological Advances in SUB

Retrieved on: 
Friday, April 9, 2021

DUBLIN, April 9, 2021 /PRNewswire/ -- The "Single-use Bioprocessing Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, April 9, 2021 /PRNewswire/ -- The "Single-use Bioprocessing Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global single-use bioprocessing market by revenue is expected to grow at a CAGR of 17% during the period 2021-2026.
  • Modalities such as covid-19 vaccine requirement, cell and gene therapies, and monoclonal antibodies are likely to influence the single-use bioprocessing market growth.
  • The global single-use bioprocessing market research report includes a detailed segmentation by product, application, end-user, method, geography.

Avantor Named Best Bioprocessing Supplier in Single-Use Manufacturing at Asia-Pacific Bioprocessing Excellence Awards 2021

Retrieved on: 
Tuesday, April 6, 2021

Singapore, Apr 6, 2021 - (ACN Newswire) - Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, was named Best Bioprocessing Supplier in Single-Use Manufacturing at the Asia-Pacific Bioprocessing Excellence Awards 2021 held recently.

Key Points: 
  • Singapore, Apr 6, 2021 - (ACN Newswire) - Avantor Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, was named Best Bioprocessing Supplier in Single-Use Manufacturing at the Asia-Pacific Bioprocessing Excellence Awards 2021 held recently.
  • Avantor was also awarded Best Company in Bioprocessing Excellence for Single-use Solutions at Biologics Manufacturing Korea 2020.
  • For information, visit avantorsciences.com and find us on:
    The Asia-Pacific Bioprocessing Excellence Awards seeks to give recognition to exceptional bioprocessing experts, organizations and technologies that facilitate biomanufacturing excellence with enhanced speed, reduced cost, and superior quality.
  • 2021 marks the fifth year of ABEA, which was first established in 2017 and backed by industry requests.

Resolutions of the Annual Shareholders' Meeting of Sartorius AG

Retrieved on: 
Friday, March 26, 2021

The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.

Key Points: 
  • The Sartorius Group is a leading international partner of life science research and the biopharmaceutical industry.
  • The Bioprocess Solutions Division with its broad product portfolio focusing on single-use solutions helps customers to manufacture biotech medications and vaccines safely and efficiently.
  • The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions complementary technologies.
  • At the end of 2020, nearly 11,000 people were employed at the Group's approximately 60manufacturing and sales sites, serving customers around the globe.